Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Hajime, Nagasawa"'
Autor:
Hajime Nagasawa, Seiji Ueda, Tomoyuki Otsuka, Kumiko Kaifu, Shigeo Ono, Teruyuki Okuma, Takashi Kobayashi, Satoshi Matsushita, Takatoshi Kasai, Tomotaka Dohi, Yoshifumi Fukushima, Atsushi Amano, Yusuke Suzuki
Publikováno v:
Journal of Pharmacological Sciences, Vol 147, Iss 1, Pp 132-137 (2021)
Hypertension and constipation are major hemodialysis complications. Salt restriction is one of the most important nonpharmacological interventions in managing hypertension. In patients undergoing hemodialysis, nonpharmacological strategies to manage
Externí odkaz:
https://doaj.org/article/cdb707b78c8d47f4a10c44659468ef9b
Autor:
Tomoyuki Otsuka, Seiji Ueda, Yasuhiko Tomino, Yusuke Suzuki, Takashi Kobayashi, Takao Urabe, Takeshi Sugaya, Hajime Nagasawa, Junko Yabuuchi, Yasuhiko Kanaguchi, Keiko Takahashi
Publikováno v:
Juntendo Medical Journal. 67:39-45
Autor:
Hajime Nagasawa, Hitoshi Suzuki, Celia Jenkinson, Seiji Ueda, Yusuke Fukao, Maiko Nakayama, Tomoyuki Otsuka, Teruyuki Okuma, Wilmelenne Clapper, Radko Komers, Yusuke Suzuki
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS gddY mice are an IgA nephropathy (IgAN)-prone mouse model that develops albuminuria by 8 weeks (wks) of age with glomerular IgA, IgG and C3 deposits and progressive mesangioproliferative glomerulonephritis. We have previously show
Autor:
Teruyuki Okuma, Seiji Ueda, Takashi Kobayashi, Hajime Nagasawa, Tomoyuki Otsuka, Masami Nakata, Koji Sato, Kumiko Kaifu, Satoshi Matsushita, Maki Murakoshi, Tomohito Gohda, Yusuke Suzuki
Publikováno v:
Journal of Hypertension. 41:e318
Autor:
Tomoyuki Otsuka, Seiji Ueda, Hajime Nagasawa, Teruyuki Okuma, Masami Nakata, Koji Sato, Takashi Kobayashi, Maki Murakoshi, Tomohito Gohda, Takanori Matsui, Shoichi Yamagishi, Yusuke Suzuki
Publikováno v:
Journal of Hypertension. 41:e374
Publikováno v:
In Kidney International Reports April 2024 9(4) Supplement:S330-S331
Autor:
Yoshifumi Fukushima, Yusuke Suzuki, Takashi Kobayashi, Tomoyuki Otsuka, Takatoshi Kasai, Shigeo Ono, Atsushi Amano, Kumiko Kaifu, Satoshi Matsushita, Tomotaka Dohi, Seiji Ueda, Teruyuki Okuma, Hajime Nagasawa
Publikováno v:
Journal of Pharmacological Sciences, Vol 147, Iss 1, Pp 132-137 (2021)
Hypertension and constipation are major hemodialysis complications. Salt restriction is one of the most important nonpharmacological interventions in managing hypertension. In patients undergoing hemodialysis, nonpharmacological strategies to manage
Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease
Autor:
Keiichi Wakabayashi, Tomoyuki Otsuka, Tomoyasu Kadoguchi, Seiji Ueda, Higashimoto Yuichiro, Nao Nohara, Tomohito Gohda, Hajime Nagasawa, Junko Yabuuchi, Sho-ichi Yamagishi, Yusuke Suzuki, Takanori Matsui
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Prevalence of sarcopenia is high in patients with chronic kidney disease (CKD), especially in those with dialysis. Various pathological conditions related to CKD, such as chronic inflammation, insulin resistance, and endothelial dysfunction, are thou
Autor:
Seiji Ueda, Yoshihito Nihei, Hajime Nagasawa, Tomohito Gohda, Yusuke Suzuki, Yusuke Fukao, Masao Kihara
Publikováno v:
CEN Case Reports
The coronavirus disease 2019 (COVID-19) pandemic is now a major global health threat. More than half a year have passed since the first discovery of severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), no effective treatment has been establis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::270add5ab8236dca6e5e380aa2fc9665
https://doi.org/10.21203/rs.3.rs-63251/v1
https://doi.org/10.21203/rs.3.rs-63251/v1
Autor:
Maiko Nakayama, Seiji Ueda, Celia Jenkinson, Yusuke Fukao, Radko Komers, Tomoyuki Otsuka, Yusuke Suzuki, Hitoshi Suzuki, Kai Liu, Hajime Nagasawa
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims gddY mice are an IgA nephropathy (IgAN)-prone mouse model that develops albuminuria by 8 weeks (wks) of age with glomerular IgA, IgG, and C3 deposits and progressive mesangioproliferative glomerulonephritis. A previous study in th